Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Roche's (RHHBY) Columvi, in combination with GemOx, achieves the primary endpoint of overall survival in a late-stage lymphoma study.
ALX Oncology (ALXO) announces positive results from an early to mid-stage study of an investigational combination regimen to treat indolent and aggressive R/R B-NHL.